Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
bmf-219 save search
Biomea Fusion Highlights Initial Data from the First Two Type 1 Diabetes Patients Dosed with BMF-219
Published: 2024-04-01 (Crawled : 13:00) - globenewswire.com
BMEA | $11.18 -2.78% -2.86% 1.7M
|
Professional, Scientific, and T...
|
| O: 2.68%
H: 5.93%
C: -0.33%
bmf-219 first diabetes
ALSTOM SA: Alstom receives an additional order for 103 MF19 new generation metros to modernise the Paris region network
Published: 2024-03-07 (Crawled : 17:00) - globenewswire.com
AOMFF | $15.15 95.45% 9.2K
|
Producer Manufacturing
|
| O: 0.46%
H: 0.76%
C: 0.76%
ALSMY | $1.51 -1.78% 650K
|
Manufacturing
|
| O: 0.0%
H: 3.2%
C: 3.2%
mf19 network order
Biomea Fusion Presents Patient Cohorts in COVALENT-111 Displaying a Durable Placebo-Adjusted Mean Reduction of up to 1.4% in HbA1c While Off Therapy at Week-26, after BMF-219’s 28-Day Treatment Cycle, Supporting Improved Pancreatic Function
Published: 2024-03-06 (Crawled : 08:00) - globenewswire.com
BMEA | $11.18 -2.78% -2.86% 1.7M
|
Professional, Scientific, and T...
|
| O: -16.72%
H: 16.45%
C: 8.29%
alent-111 pancreatic treatment therapy
Biomea Fusion Announces Dosing of First Type 1 Diabetes Patient in Phase II Study (COVALENT-112) with BMF-219
Published: 2024-01-08 (Crawled : 14:00) - globenewswire.com
BMEA | $11.18 -2.78% -2.86% 1.7M
|
Professional, Scientific, and T...
|
| O: 0.61%
H: 7.77%
C: 7.7%
alent-112 first bmf-219 diabetes study
Biomea Fusion Presents Achievement of Minimal Residual Disease Negativity (MRD-neg) in First Complete Responder from Ongoing Phase I Study (COVALENT-101) of BMF-219
Published: 2023-12-11 (Crawled : 16:00) - biospace.com/
BMEA | $11.18 -2.78% -2.86% 1.7M
|
Professional, Scientific, and T...
|
| O: -24.51%
H: 1.49%
C: -7.69%
alent-101 first disease ongoing bmf-219 study
Biomea Fusion Presents Achievement of Minimal Residual Disease Negativity (MRD-neg) in First Complete Responder from Ongoing Phase I Study (COVALENT-101) of BMF-219 in Patients with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) at the 2023 ASH Annual Meeting
Published: 2023-12-11 (Crawled : 14:30) - globenewswire.com
BMEA | $11.18 -2.78% -2.86% 1.7M
|
Professional, Scientific, and T...
|
| O: -24.51%
H: 1.49%
C: -7.69%
alent-101 first disease ongoing bmf-219 meeting leukemia study
Biomea Fusion Presents Long-Term Follow-Up Data Showing Improved Glycemic Control after 22 Weeks Off Treatment in Ongoing Phase II Study (COVALENT-111) of BMF-219 in Adults with Type 2 Diabetes
Published: 2023-12-08 (Crawled : 15:30) - biospace.com/
BMEA | $11.18 -2.78% -2.86% 1.7M
|
Professional, Scientific, and T...
|
| O: 3.59%
H: 10.15%
C: 8.48%
alent-111 control treatment ongoing bmf-219 diabetes study
Biomea Fusion Presents Long-Term Follow-Up Data Showing Improved Glycemic Control after 22 Weeks Off Treatment in Ongoing Phase II Study (COVALENT-111) of BMF-219 in Adults with Type 2 Diabetes in a Poster Presentation at the World Congress Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)
Published: 2023-12-08 (Crawled : 14:00) - globenewswire.com
BMEA | $11.18 -2.78% -2.86% 1.7M
|
Professional, Scientific, and T...
|
| O: 3.59%
H: 10.15%
C: 8.48%
alent-111 disease congress control world presentation treatment ongoing bmf-219 diabetes cardiovascular insulin study
Biomea Fusion to Present Long-Term Follow-Up Data from Ongoing Phase II Study (COVALENT-111) of BMF-219 in Adults with Type 2 Diabetes and Results from Ex-Vivo Human Islet Experiments at the World Congress Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)
Published: 2023-12-07 (Crawled : 14:30) - globenewswire.com
BMEA | $11.18 -2.78% -2.86% 1.7M
|
Professional, Scientific, and T...
|
| O: 0.0%
H: 10.89%
C: -18.54%
alent-111 disease congress world ongoing bmf-219 diabetes cardiovascular results insulin study
Biomea Fusion Announces Health Canada Clearance of Clinical Trial Application (CTA) for BMF-219 in Type 1 Diabetes
Published: 2023-12-05 (Crawled : 13:30) - globenewswire.com
BMEA | $11.18 -2.78% -2.86% 1.7M
|
Professional, Scientific, and T...
|
| O: 5.76%
H: 3.01%
C: -9.69%
bmf-219 health clearance canada application trial diabetes
Biomea Fusion Abstract “BMF-219: A Novel Therapeutic Agent to Reestablish Functional Beta Cells and Provide Long-term Glycemic Control" Selected as One of Six Oral Presentations at 21st World Congress Insulin Resistance, Diabetes & Cardiovascular Disease
Published: 2023-11-16 (Crawled : 13:30) - globenewswire.com
BMEA | $11.18 -2.78% -2.86% 1.7M
|
Professional, Scientific, and T...
|
| O: -0.11%
H: 6.94%
C: 0.32%
bmf-219 disease six congress world one diabetes cardiovascular insulin
Biomea Fusion to Present New Data from Ongoing Phase II Study (COVALENT-111) of BMF-219 in Patients with Type 2 Diabetes at the World Congress Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)
Published: 2023-11-08 (Crawled : 21:00) - globenewswire.com
BMEA | $11.18 -2.78% -2.86% 1.7M
|
Professional, Scientific, and T...
|
| O: 0.77%
H: 1.95%
C: -6.12%
alent-111 disease congress world ongoing bmf-219 diabetes cardiovascular insulin study
Biomea Fusion Announces FDA Clearance of Investigational New Drug (IND) Application for BMF-219 in Type 1 Diabetes
Published: 2023-10-05 (Crawled : 12:30) - globenewswire.com
BMEA | $11.18 -2.78% -2.86% 1.7M
|
Professional, Scientific, and T...
|
| O: 0.57%
H: 0.16%
C: -0.73%
bmf-219 fda drug clearance application diabetes
BMF-219 Induces Complete Responses in Target Acute Myeloid Leukemia (AML) Patient Population
Published: 2023-07-24 (Crawled : 13:00) - globenewswire.com
BMEA | $11.18 -2.78% -2.86% 1.7M
|
Professional, Scientific, and T...
|
| O: 6.83%
H: 0.3%
C: -20.04%
bmf-219 leukemia
Biomea Fusion Presents Positive Clinical Data from the Initial Cohorts of the Ongoing Phase II Study (COVALENT-111) of BMF-219 in Patients with Type 2 Diabetes Mellitus at the American Diabetes Association (ADA) 83rd Scientific Sessions; 100 mg Cohort 3 Demonstrated a 90% Response Rate and 70% Maintained or Improved Time in (Normal Glucose) Range, While Off-Treatment
Published: 2023-06-24 (Crawled : 04:20) - globenewswire.com
BMEA | $11.18 -2.78% -2.86% 1.7M
|
Professional, Scientific, and T...
| Email alert
Add to watchlist
alent-111 association positive ongoing bmf-219 response diabetes 100 study
Biomea Fusion to Present Late Breaking Data from Ongoing Phase II Trial, COVALENT-111, Evaluating BMF-219 in Patients with Type 2 Diabetes at ADA 2023
Published: 2023-06-20 (Crawled : 20:00) - globenewswire.com
BMEA | $11.18 -2.78% -2.86% 1.7M
|
Professional, Scientific, and T...
|
| O: -1.18%
H: 2.52%
C: -2.37%
JNJ | News | $145.74 0.67% 0.0% 9.3M
|
Health Technology
|
| O: -0.34%
H: 0.82%
C: 0.18%
alent-111 ongoing bmf-219 diabetes
Biomea Fusion to Present Late Breaking Data from Ongoing Phase II Trial, COVALENT-111, Evaluating BMF-219 in Patients with Type 2 Diabetes, at the ADA 83rd Scientific Sessions 2023 in June
Published: 2023-04-19 (Crawled : 13:00) - globenewswire.com
BMEA | $11.18 -2.78% -2.86% 1.7M
|
Professional, Scientific, and T...
|
| O: 3.08%
H: 6.29%
C: 2.61%
alent-111 sessions ongoing bmf-219
Biomea Fusion Announces Positive Data from Initial Cohorts of Ongoing Phase II Study (COVALENT-111) of BMF-219 in Patients with Type 2 Diabetes; 100 mg Cohort 3 Demonstrated an 89% Response Rate and 1% Median Reduction in HbA1c at Day 28
Published: 2023-03-28 (Crawled : 22:00) - globenewswire.com
BMEA | $11.18 -2.78% -2.86% 1.7M
|
Professional, Scientific, and T...
|
| O: 49.06%
H: 37.13%
C: 33.52%
alent-111 day positive ongoing bmf-219 response 100 study
Biomea Fusion Announces Positive Data from Initial Cohorts of Ongoing Phase II Study (COVALENT-111) of BMF-219 in Patients with Type 2 Diabetes
Published: 2023-03-28 (Crawled : 13:00) - biospace.com/
BMEA | $11.18 -2.78% -2.86% 1.7M
|
Professional, Scientific, and T...
|
| O: 49.06%
H: 37.13%
C: 33.52%
alent-111 positive ongoing bmf-219 diabetes study
Biomea Fusion to Host Conference Call and Webcast to Discuss Initial Phase II Clinical Data for BMF-219 in Subjects with Type 2 Diabetes on March 28th, 2023 at 8:30 a.m. ET
Published: 2023-03-23 (Crawled : 12:20) - globenewswire.com
BMEA | $11.18 -2.78% -2.86% 1.7M
|
Professional, Scientific, and T...
|
| O: 0.0%
H: 7.99%
C: 5.26%
bmf-219 conference diabetes
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
AGBA | News | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $1.45 5.84% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.421 97.65% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | News | $0.92 84.0% 45.65% 1.6M
|
OST | $0.509 23.81% 45.26% 90K
|
GDHG | $0.263 21.76% 40.66% 3.1M
|
XPON | News | $3.1 60.62% 37.74% 17M
|
TIRX | $0.8 65.02% 30.74% 58M
|
BNTC | News | $6.92 44.17% 30.64% 3.5M
|
Health Technology
Your saved searches
Save your searches and get alerts when important news are released.